Search research articles
Contact Us
Filters
Showing results (81-90 of 159) with videos related to
Page
of 16
Sort By:
Molecular Oncology
|
May 21, 2021
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
Dorte Schou Nørøxe, Aidan Flynn, Christina Westmose Yde, et al.
Targeted Oncology
|
August 28, 2015
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
Rodrigo Dienstmann, Ulrik Lassen, Jonathan Cebon, et al.
Journal of Neuro-Oncology
|
July 16, 2025
Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study
Maya Jeje Schuang Lü, Signe Regner Michaelsen, Alessio Locallo, et al.
Neuro-Oncology Advances
|
March 27, 2026
Noninvasive detection and monitoring of glioblastoma subtypes via dual-marker plasma proteomics
Patricia Rojas-Sanchez, Kirstine Juul-Elbaek, Henriette Pedersen, et al.
Genome Biology
|
January 29, 2026
Resolving clonal evolution and selection of extrachromosomal DNA at single-cell resolution
Josephine Deleuran Hendriksen, Alessio Locallo, Balthasar Clemens Schlotmann, et al.
Molecular Oncology
|
March 6, 2020
Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
Thomas Urup, Linn Gillberg, Katja Kaastrup, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|
January 21, 2023
Characteristics of de novo cancer in liver transplant recipients
Tine Holm Riis, Dina Leth Møller, Julie Høgh, et al.
Neuro-Oncology Advances
|
December 13, 2023
The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients
Dorte Schou Nørøxe, Simone Maarup, Vincent Fougner, et al.
Molecular Oncology
|
June 6, 2016
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, et al.
Oncotarget
|
March 13, 2019
Application of cell-free DNA for genomic tumor profiling: a feasibility study
Lise B Ahlborn, Kristoffer S Rohrberg, Migle Gabrielaite, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 159) with videos related to
Sort By:
Page
of 16
Molecular Oncology
|
May 21, 2021
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
Dorte Schou Nørøxe, Aidan Flynn, Christina Westmose Yde, et al.
Targeted Oncology
|
August 28, 2015
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors
Rodrigo Dienstmann, Ulrik Lassen, Jonathan Cebon, et al.
Journal of Neuro-Oncology
|
July 16, 2025
Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case study
Maya Jeje Schuang Lü, Signe Regner Michaelsen, Alessio Locallo, et al.
Neuro-Oncology Advances
|
March 27, 2026
Noninvasive detection and monitoring of glioblastoma subtypes via dual-marker plasma proteomics
Patricia Rojas-Sanchez, Kirstine Juul-Elbaek, Henriette Pedersen, et al.
Genome Biology
|
January 29, 2026
Resolving clonal evolution and selection of extrachromosomal DNA at single-cell resolution
Josephine Deleuran Hendriksen, Alessio Locallo, Balthasar Clemens Schlotmann, et al.
Molecular Oncology
|
March 6, 2020
Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
Thomas Urup, Linn Gillberg, Katja Kaastrup, et al.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|
January 21, 2023
Characteristics of de novo cancer in liver transplant recipients
Tine Holm Riis, Dina Leth Møller, Julie Høgh, et al.
Neuro-Oncology Advances
|
December 13, 2023
The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients
Dorte Schou Nørøxe, Simone Maarup, Vincent Fougner, et al.
Molecular Oncology
|
June 6, 2016
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, et al.
Oncotarget
|
March 13, 2019
Application of cell-free DNA for genomic tumor profiling: a feasibility study
Lise B Ahlborn, Kristoffer S Rohrberg, Migle Gabrielaite, et al.
Page
of 16